Main N6-Methyladenosine Readers: YTH Family Proteins in Cancers

Among the over 150 RNA modifications, N6-methyladenosine (m6A) is the most abundant internal modification in eukaryotic RNAs, not only in messenger RNAs, but also in microRNAs and long non-coding RNAs. It is a dynamic and reversible process in mammalian cells, which is installed by "writers,&qu...

Full description

Saved in:
Bibliographic Details
Published inFrontiers in oncology Vol. 11; p. 635329
Main Authors Dai, Xin-Yuan, Shi, Liang, Li, Zhi, Yang, Hai-Yan, Wei, Ji-Fu, Ding, Qiang
Format Journal Article
LanguageEnglish
Published Switzerland Frontiers Media S.A 13.04.2021
Subjects
cancer
cancer therapy
IYT521-B homology domain proteins
N6-methyladenosine
Oncology
RNA metabolism
cancer therapy
N6-methyladenosine
cancer
IYT521-B homology domain proteins
RNA metabolism
Online AccessGet full text

Cover

More Information
Summary:Among the over 150 RNA modifications, N6-methyladenosine (m6A) is the most abundant internal modification in eukaryotic RNAs, not only in messenger RNAs, but also in microRNAs and long non-coding RNAs. It is a dynamic and reversible process in mammalian cells, which is installed by "writers," consisting of METTL3, METTL14, WTAP, RBM15/15B, and KIAA1429 and removed by "erasers," including FTO and ALKBH5. Moreover, m6A modification is recognized by "readers," which play the key role in executing m6A functions. IYT521-B homology (YTH) family proteins are the first identified m6A reader proteins. They were reported to participate in cancer tumorigenesis and development through regulating the metabolism of targeted RNAs, including RNA splicing, RNA export, translation, and degradation. There are many reviews about function of m6A and its role in various diseases. However, reviews only focusing on m6A readers, especially YTH family proteins are few. In this review, we systematically summarize the recent advances in structure and biological function of YTH family proteins, and their roles in human cancer and potential application in cancer therapy.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
Reviewed by: Ping Yi, Third Affiliated Hospital of Chongqing Medical University, China; Ye Fu, Plaisance Capital Management, United States
This article was submitted to Molecular and Cellular Oncology, a section of the journal Frontiers in Oncology
Edited by: Lorenzo Gerratana, University of Udine, Italy
These authors have contributed equally to this work
ISSN:2234-943X
2234-943X
DOI:10.3389/fonc.2021.635329